109906
论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
- 3.4 Breast Cancer (Dove Med Press)
- 3.2 Clin Epidemiol
- 2.6 Cancer Manag Res
- 2.9 Infect Drug Resist
- 3.7 Clin Interv Aging
- 5.1 Drug Des Dev Ther
- 3.1 Int J Chronic Obstr
- 6.6 Int J Nanomed
- 2.6 Int J Women's Health
- 2.9 Neuropsych Dis Treat
- 2.8 OncoTargets Ther
- 2.0 Patient Prefer Adher
- 2.2 Ther Clin Risk Manag
- 2.5 J Pain Res
- 3.0 Diabet Metab Synd Ob
- 3.2 Psychol Res Behav Ma
- 3.4 Nat Sci Sleep
- 1.8 Pharmgenomics Pers Med
- 2.0 Risk Manag Healthc Policy
- 4.1 J Inflamm Res
- 2.0 Int J Gen Med
- 3.4 J Hepatocell Carcinoma
- 3.0 J Asthma Allergy
- 2.2 Clin Cosmet Investig Dermatol
- 2.4 J Multidiscip Healthc
已发表论文
系统免疫炎症指数在初发非 M3 型急性髓系白血病患者中的预后意义
Authors Nan H , Yang P, Wang L, Li W, Liu Y, Huang F, Xu F, Shi M , Bai Y
Received 10 July 2025
Accepted for publication 1 November 2025
Published 21 November 2025 Volume 2025:18 Pages 16331—16346
DOI https://doi.org/10.2147/JIR.S552797
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Subhasis Chattopadhyay
Huijie Nan,1,* Peiyao Yang,1,* Lijie Wang,2,* Wenqian Li,1 Yuanyuan Liu,2 Fei Huang,3 Fangfang Xu,4 Mingyue Shi,1,* Yanliang Bai1,*
1Department of Hematology, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China; 2Department of Hematology, Henan University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China; 3Department of General Surgery, Handan Iron and Steel Group Hospital, Handan, Hebei, People’s Republic of China; 4Department of Geriatric Medicine, Key Laboratory of Geriatric Medicine, Institute of Geriatric Medicine, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Mingyue Shi, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China, Email shimingyue16@gmail.com Yanliang Bai, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China, Email yanliangbai@126.com
Purpose: The systemic immune-inflammation index (SII), integrating peripheral neutrophil, platelet, and lymphocyte counts, demonstrates proven prognostic value across malignancies. Its clinical utility in de novo non-M3 acute myeloid leukemia (AML) remains underexplored.
Patients and Methods: This retrospective study established the prognostic significance of SII in 262 non-M3 AML patients (diagnosed April 2016–April 2021) and developed a validated survival nomogram. Optimal SII stratification thresholds were determined by X-tile analysis. Clinical characteristics, induction response, overall survival (OS) and event-free survival (EFS) were analyzed. Multivariable Cox regression identified independent prognostic factors for nomogram construction. Model validation included C-index, calibration curves, time-dependent ROC analysis, and decision curve assessment (DCA).
Results: X-tile identified 43.3× 109/L as the optimal SII cutoff. High SII (≥ 43.3× 109/L) correlated with inferior median OS (11 vs 66 months; P< 0.001) and EFS (8 vs 20 months; P< 0.001) versus low SII. Subgroup analysis revealed the adverse prognostic impact of high SII was particularly evident in patients aged < 60 years, those with favorable 2022 ELN risk, and non-transplant recipients. The multivariate analysis pinpointed SII≥ 43.3× 109/L (Hazard Ratio [HR]=1.781, 95% Confidence Interval [CI]:1.264– 2.509, P=0.001) as a significant independent predictor of OS. Additionally, age, white blood cell (WBC) count ≥ 100× 109/L, 2022 ELN risk classification, and receiving HSCT were also independent predictors of OS. Based on these independent predictors, we developed a prognostic nomogram. The nomogram demonstrated good discriminatory ability (C-index: 0.715), accurate calibration, and provided clinical net benefit in DCA. Moreover, the time-dependent ROC AUCs for 1-, 2-, and 3-year OS were 0.781, 0.752 and 0.781, respectively.
Conclusion: SII is an independent prognostic marker in de novo non-M3 AML. The proposed nomogram, incorporating both SII and established prognostic variables, enables precise and individualized survival prediction. This tool has the potential to inform risk-adapted treatment strategies and guide decision-making in clinical practice.
Keywords: inflammatory biomarker, hematologic malignancy, risk stratification, survival prediction model
1Department of Hematology, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China; 2Department of Hematology, Henan University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, People’s Republic of China; 3Department of General Surgery, Handan Iron and Steel Group Hospital, Handan, Hebei, People’s Republic of China; 4Department of Geriatric Medicine, Key Laboratory of Geriatric Medicine, Institute of Geriatric Medicine, Henan Provincial People’s Hospital, People’s Hospital of Zhengzhou University, Zhengzhou, Henan, People’s Republic of China
*These authors contributed equally to this work
Correspondence: Mingyue Shi, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China, Email shimingyue16@gmail.com Yanliang Bai, Zhengzhou University People’s Hospital and Henan Provincial People’s Hospital, Zhengzhou, Henan, 450003, People’s Republic of China, Email yanliangbai@126.com
Purpose: The systemic immune-inflammation index (SII), integrating peripheral neutrophil, platelet, and lymphocyte counts, demonstrates proven prognostic value across malignancies. Its clinical utility in de novo non-M3 acute myeloid leukemia (AML) remains underexplored.
Patients and Methods: This retrospective study established the prognostic significance of SII in 262 non-M3 AML patients (diagnosed April 2016–April 2021) and developed a validated survival nomogram. Optimal SII stratification thresholds were determined by X-tile analysis. Clinical characteristics, induction response, overall survival (OS) and event-free survival (EFS) were analyzed. Multivariable Cox regression identified independent prognostic factors for nomogram construction. Model validation included C-index, calibration curves, time-dependent ROC analysis, and decision curve assessment (DCA).
Results: X-tile identified 43.3× 109/L as the optimal SII cutoff. High SII (≥ 43.3× 109/L) correlated with inferior median OS (11 vs 66 months; P< 0.001) and EFS (8 vs 20 months; P< 0.001) versus low SII. Subgroup analysis revealed the adverse prognostic impact of high SII was particularly evident in patients aged < 60 years, those with favorable 2022 ELN risk, and non-transplant recipients. The multivariate analysis pinpointed SII≥ 43.3× 109/L (Hazard Ratio [HR]=1.781, 95% Confidence Interval [CI]:1.264– 2.509, P=0.001) as a significant independent predictor of OS. Additionally, age, white blood cell (WBC) count ≥ 100× 109/L, 2022 ELN risk classification, and receiving HSCT were also independent predictors of OS. Based on these independent predictors, we developed a prognostic nomogram. The nomogram demonstrated good discriminatory ability (C-index: 0.715), accurate calibration, and provided clinical net benefit in DCA. Moreover, the time-dependent ROC AUCs for 1-, 2-, and 3-year OS were 0.781, 0.752 and 0.781, respectively.
Conclusion: SII is an independent prognostic marker in de novo non-M3 AML. The proposed nomogram, incorporating both SII and established prognostic variables, enables precise and individualized survival prediction. This tool has the potential to inform risk-adapted treatment strategies and guide decision-making in clinical practice.
Keywords: inflammatory biomarker, hematologic malignancy, risk stratification, survival prediction model